[
  {
    "ts": null,
    "headline": "Top Stock Reports for Exxon Mobil, AMD & Caterpillar",
    "summary": "Exxon Mobil advances key projects, AMD rides EPYC and AI demand, and Caterpillar gains on Energy & Transportation strength.",
    "url": "https://finnhub.io/api/news?id=86c5279c7dbca5aaaa385ebd9a8d371428d0b9baf75e6a26dfa986cb6c59bf41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758145680,
      "headline": "Top Stock Reports for Exxon Mobil, AMD & Caterpillar",
      "id": 136797598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Exxon Mobil advances key projects, AMD rides EPYC and AI demand, and Caterpillar gains on Energy & Transportation strength.",
      "url": "https://finnhub.io/api/news?id=86c5279c7dbca5aaaa385ebd9a8d371428d0b9baf75e6a26dfa986cb6c59bf41"
    }
  },
  {
    "ts": null,
    "headline": "Advancing Cancer Research Brings New Hope for Patients Worldwide",
    "summary": "Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu",
    "url": "https://finnhub.io/api/news?id=e90ffbbb1f9a108a48e6589f09ac2a7c2994f01614980d5d4cd85acc1f09fd61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758115800,
      "headline": "Advancing Cancer Research Brings New Hope for Patients Worldwide",
      "id": 136789051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu",
      "url": "https://finnhub.io/api/news?id=e90ffbbb1f9a108a48e6589f09ac2a7c2994f01614980d5d4cd85acc1f09fd61"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Dividend",
    "summary": "PRINCETON, N.J., September 17, 2025--Bristol Myers Squibb Announces Dividend",
    "url": "https://finnhub.io/api/news?id=a7d0044ff64367a7cc253535a48e50da7da1490da81d2f960c2a87cbf3228ad2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758110340,
      "headline": "Bristol Myers Squibb Announces Dividend",
      "id": 136787639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., September 17, 2025--Bristol Myers Squibb Announces Dividend",
      "url": "https://finnhub.io/api/news?id=a7d0044ff64367a7cc253535a48e50da7da1490da81d2f960c2a87cbf3228ad2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers to sell 60% stake in China joint venture",
    "summary": "SHANGHAI (Reuters) -U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.  The spokesperson said Bristol Myers was \"committed to supporting all impacted employees\" and was \"grateful for their contributions\", but said it does not comment on transaction details, citing policy.  Established in 1982, the Sino-American Shanghai Squibb Pharmaceuticals Limited (SASS) joint venture was the first Sino-U.S. pharmaceutical joint venture in the country.",
    "url": "https://finnhub.io/api/news?id=6b4ef35904b6cca212c86b89a71dffbc6d1fe9ecd4c9177241e6ac7d2150cbf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758085450,
      "headline": "Bristol Myers to sell 60% stake in China joint venture",
      "id": 136787640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SHANGHAI (Reuters) -U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.  The spokesperson said Bristol Myers was \"committed to supporting all impacted employees\" and was \"grateful for their contributions\", but said it does not comment on transaction details, citing policy.  Established in 1982, the Sino-American Shanghai Squibb Pharmaceuticals Limited (SASS) joint venture was the first Sino-U.S. pharmaceutical joint venture in the country.",
      "url": "https://finnhub.io/api/news?id=6b4ef35904b6cca212c86b89a71dffbc6d1fe9ecd4c9177241e6ac7d2150cbf3"
    }
  }
]